- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.07. | Panel urges FDA to remove warnings on hormonal menopause therapy | ||
| 18.07. | Bristol Myers' Reblozyl falls short in Phase 3; Blenrep voted down by FDA panel | ||
| 18.07. | Patient reportedly dies in Sarepta study of limb-girdle gene therapy | ||
| 17.07. | Biotech startup funding dried up in second quarter, HSBC finds | ||
| 17.07. | Novartis CEO says resolution on Trump plan to cut US drug prices will take time | ||
| 17.07. | Bristol Myers, Pfizer to offer Eliquis at a discount for some patients | ||
| 16.07. | Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks | ||
| 16.07. | AstraZeneca rare disease drug fails key trial tests | ||
| 16.07. | J&J absorbs Stelara, tariff hits to deliver beat-and-raise quarter | ||
| 16.07. | Moderna's latest approval again reveals FDA rift over COVID vaccines | ||
| 16.07. | 33 states pick up CMS program to pay for sickle cell gene therapies | ||
| 15.07. | Cancer drugmaker LaNova to sell to China's Sino Biopharm | ||
| 15.07. | Hengrui, Kailera say dual-acting obesity shot succeeds in China study | ||
| 15.07. | Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug | ||
| 14.07. | AstraZeneca blood pressure drug succeeds in late-stage trial | ||
| 14.07. | Private equity firms back PCI Pharma in bet on drug production | ||
| 14.07. | FDA rejects Ultragenyx gene therapy over manufacturing concerns | ||
| 14.07. | Takeda to seek approval of new kind of narcolepsy drug after study data | ||
| 14.07. | From data to decisions: How pharma can move faster without sacrificing trust | ||
| 11.07. | Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update | ||
| 11.07. | With Verona Pharma deal, Merck wagers on strength of lung drug's patents | ||
| 11.07. | FDA turns back Capricor's Duchenne cell therapy | ||
| 10.07. | Soleno sales of new Prader-Willi drug rise faster than expected | ||
| 10.07. | Moderna COVID vaccine gets full approval for children | ||
| 10.07. | FDA, in policy shift, publishes some drug rejection letters |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .